CCRP Therapeutics

What CCRP Therapeutics does

CCRP Therapeutics GmbH is a Berlin-based pre-clinical biopharmaceutical spin-off of Charité's Center for Cardiovascular Research (CCR), developing a single platform of first-in-class small molecule drugs called renin/prorenin receptor blockers (RERBs). The core technology targets the renin/prorenin receptor (RER/(P)RR) directly — a pathophysiological nodal point that mediates pro-proliferative signaling in cancer and angiotensin II-independent end-organ damage. Unlike direct renin inhibitors such as aliskiren, which only block the enzymatic activity of renin, RERBs block the receptor itself and downstream adapter proteins, inhibiting constitutive ligand-independent signaling through the Wnt/beta-catenin, MAPK, PI3K, and PDH pathways.

The pipeline is split across two therapeutic areas: (1) oncology indications including colorectal, pancreatic, and hepatocellular carcinoma as well as sarcoma, currently at the start of preclinical development; and (2) cardiorenal indications including diabetic nephropathy, diabetic retinopathy, and heart failure, currently in lead optimization. Proof-of-concept rests on preclinical animal-model evidence showing that RER inhibition prevents or abolishes cardiac fibrosis and diabetic nephropathy, including in AT1 receptor knockout mice, and that post-MI RER blockade reduces infarct size and improves cardiac function. The company has filed European patent application EP 2 896 692 A1 (filed July 22, 2015) covering cancer markers and applications related to (pro)renin receptor targeting.

Commercially, CCRP operates as an outsourced B2B drug discovery entity with 1-10 employees based at Hessische Strasse 3-4, Berlin. Discovery and preclinical work is executed through contract research organizations Evotec AG and Experimental Pharmacology & Oncology (EPO) GmbH, while the internal team (CEO Dmitry Kuznetsov since 2023, PD Dr. Heiko Funke-Kaiser, Prof. Thomas Unger, and the late Prof. Werner Skuballa) provides scientific direction and fundraising. The intended revenue model is licensing and co-development partnerships with larger pharmaceutical companies for clinical development and commercialization; no commercial products, customers, or revenue exist today, and no funding rounds or institutional investors are disclosed.

Name

CCRP Therapeutics

Legal name

CCRP Therapeutics GmbH

Website

https://ccrp-therapeutics.com

Company type

Private

Operating status

Operating

Headcount range

1–10 employees

Short description

CCRP Therapeutics GmbH is a Berlin-based pre-clinical biopharmaceutical spin-off of Charité developing first-in-class small molecule renin/prorenin receptor blockers (RERBs) for oncology and cardiorenal indications, with planned monetization through pharmaceutical licensing partnerships.

Ownership category

akta.pro rank

Product category

Biopharmaceutical Drug Discovery

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Lead Optimization & Preclinical Candidate Selection (HLAIALAB)

akta.pro secondary industry

Drug Discovery (Target ID/Validation & Hit Discovery) (HLAIALAA)

Keywords

• Small molecule drugs
• Oncology therapeutics
• Cardiorenal therapeutics
• Receptor blockers
• Preclinical drug discovery

Headquarters

HQ city

Berlin

HQ country

Germany

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Drug Development and Licensing: Pre-clinical biopharmaceutical company developing novel small molecule RERBs. Revenue model will likely involve licensing agreements and partnerships with larger pharmaceutical companies for clinical development, regulatory approval, and commercialization. No commercial products or revenue currently.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

CCRP Therapeutics discovers and develops first-in-class small molecule renin/prorenin receptor blockers (RERBs) targeting the (pro)renin receptor (RER) for the treatment of multiple oncological malignancies (colorectal cancer, pancreatic cancer, hepatocellular carcinoma, sarcoma) and end-organ damage caused by diabetes and hypertension (diabetic nephropathy, diabetic retinopathy, heart failure). The company collaborates with CROs Evotec AG and Experimental Pharmacology & Oncology (EPO) GmbH for drug discovery research, with oncology candidates in preclinical development and cardiorenal candidates in lead optimization.

Product overview

CCRP Therapeutics is developing a single pipeline of first-in-class small molecule drugs called renin/prorenin receptor blockers (RERBs). The company's lead program targets the renin/prorenin receptor (RER), a novel oncological and cardiovascular drug target. The RERB pipeline is being developed for two therapeutic areas: (1) oncology indications including colorectal cancer, pancreatic cancer, hepatocellular carcinoma, and sarcoma, currently in preclinical development; and (2) cardiorenal indications including diabetic nephropathy, diabetic retinopathy, and heart failure, currently in lead optimization. The company collaborates with Evotec AG and Experimental Pharmacology & Oncology (EPO) GmbH for drug discovery research.

Differentiator

Problem solved

Functional benefit

Products and services

• Renin/Prorenin Receptor Blockers (RERBs) First-in-class small molecule drug class that blocks the renin/prorenin receptor (RER/(P)RR) and its downstream adapter proteins, inhibiting constitutive (ligand-independent) signaling pathways including Wnt/beta-catenin, MAPK, PI3K, and PDH pathways. Developed for oncological indications (colorectal, pancreatic, hepatocellular carcinoma, sarcoma) and cardiorenal end-organ damage (diabetic nephropathy, diabetic retinopathy, heart failure).

Quantifiable outcome

• Animal models demonstrated that inhibition of (pro)renin binding to the RER by decoy peptide can prevent or even abolish the development of cardiac fibrosis and diabetic nephropathy, even in AT1 receptor knockout mice.
• +1 more outcomes

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Three partnerships are on record, tiered core.

• Evotec AGcoreTechnology or IntegrationContract research organization (CRO) cooperating with CCRP Therapeutics for first-in-class small molecule drug discovery and development of renin/prorenin receptor blockers (RERBs) for oncological and cardiorenal indications.
• Experimental Pharmacology & Oncology (EPO) GmbHcoreTechnology or IntegrationContract research organization (CRO) collaborating with CCRP Therapeutics for drug discovery and preclinical development of RERBs for oncology and cardiorenal indications.
• Charité Center for Cardiovascular Research (CCR)coreStrategic or Co-development PartnerParent academic institution and origin of CCRP Therapeutics spin-off. CCR provides ongoing research collaboration, scientific expertise in cardiovascular research, and connection to academic network for continued research and development.

Scale indicators1 record

Recent moves6 records

Expansion highlights5 records

Market position

Strengths4 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/ccrp-therapeutics-gmbh

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CCRP Therapeutics